BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 25064748)

  • 1. Will post-transplantation cell therapies for pediatric patients become standard of care?
    Lankester AC; Locatelli F; Bader P; Rettinger E; Egeler M; Katewa S; Pulsipher MA; Nierkens S; Schultz K; Handgretinger R; Grupp SA; Boelens JJ; Bollard CM;
    Biol Blood Marrow Transplant; 2015 Mar; 21(3):402-11. PubMed ID: 25064748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pilot study of prophylactic ex vivo costimulated donor leukocyte infusion after reduced-intensity conditioned allogeneic stem cell transplantation.
    Kumar AJ; Hexner EO; Frey NV; Luger SM; Loren AW; Reshef R; Boyer J; Smith J; Stadtmauer EA; Levine BL; June CH; Porter DL; Goldstein SC
    Biol Blood Marrow Transplant; 2013 Jul; 19(7):1094-101. PubMed ID: 23635453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful treatment of stem cell graft failure in pediatric patients using a submyeloablative regimen of campath-1H and fludarabine.
    Ahmed N; Leung KS; Rosenblatt H; Bollard CM; Gottschalk S; Myers GD; Carrum G; Heslop HE; Brenner MK; Krance RA
    Biol Blood Marrow Transplant; 2008 Nov; 14(11):1298-304. PubMed ID: 18940685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Donor lymphocyte infusions for relapse after allogeneic transplantation: when, if and for whom?
    Chang YJ; Huang XJ
    Blood Rev; 2013 Jan; 27(1):55-62. PubMed ID: 23261066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liver graft-versus-host disease after donor lymphocyte infusion for relapses of hematologic malignancies post allogeneic hematopoietic stem cell transplantation.
    Ma SY; Au WY; Lie AK; Ng IO; Leung AY; Tse EW; Liang RH; Lau GK; Kwong YL
    Bone Marrow Transplant; 2004 Jul; 34(1):57-61. PubMed ID: 15156162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation.
    Roddie C; Peggs KS
    Expert Opin Biol Ther; 2011 Apr; 11(4):473-87. PubMed ID: 21269237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modified donor lymphocyte infusion-associated acute graft-versus-host disease after haploidentical T-cell-replete hematopoietic stem cell transplantation: incidence and risk factors.
    Yan CH; Liu DH; Xu LP; Liu KY; Zhao T; Wang Y; Chen H; Chen YH; Han W; Huang XJ
    Clin Transplant; 2012; 26(6):868-76. PubMed ID: 22432715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD4+CD25+ regulatory T cell depletion improves the graft-versus-tumor effect of donor lymphocytes after allogeneic hematopoietic stem cell transplantation.
    Maury S; Lemoine FM; Hicheri Y; Rosenzwajg M; Badoual C; Cheraï M; Beaumont JL; Azar N; Dhedin N; Sirvent A; Buzyn A; Rubio MT; Vigouroux S; Montagne O; Bories D; Roudot-Thoraval F; Vernant JP; Cordonnier C; Klatzmann D; Cohen JL
    Sci Transl Med; 2010 Jul; 2(41):41ra52. PubMed ID: 20650872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cell composition of infused donor lymphocyte has different impact in different types of allogeneic hematopoietic stem cell transplantation.
    Zhao XS; Wang Y; Yan CH; Wang JZ; Zhang XH; Xu LP; Liu KY; Huang XJ
    Clin Transplant; 2014 Aug; 28(8):926-34. PubMed ID: 24931494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy followed by modified donor lymphocyte infusion as a treatment for relapsed acute leukemia after haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion: superior outcomes compared with chemotherapy alone and an analysis of prognostic factors.
    Yan CH; Wang JZ; Liu DH; Xu LP; Chen H; Liu KY; Huang XJ
    Eur J Haematol; 2013 Oct; 91(4):304-14. PubMed ID: 23837640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunobiology of allogeneic hematopoietic stem cell transplantation.
    Welniak LA; Blazar BR; Murphy WJ
    Annu Rev Immunol; 2007; 25():139-70. PubMed ID: 17129175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical options after failure of allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies.
    Petrovic A; Hale G
    Expert Rev Clin Immunol; 2011 Jul; 7(4):515-25; quiz 526-7. PubMed ID: 21787195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-dose methotrexate for the treatment of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
    Huang XJ; Jiang Q; Chen H; Xu L; Liu D; Chen Y; Han W; Zhang Y; Liu K; Lu D
    Bone Marrow Transplant; 2005 Aug; 36(4):343-8. PubMed ID: 15968295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased bacterial infections after transfusion of leukoreduced non-irradiated blood products in recipients of allogeneic stem cell transplants after reduced-intensity conditioning.
    Jaime-Pérez JC; Villarreal-Villarreal CD; Salazar-Riojas R; Méndez-Ramírez N; Vázquez-Garza E; Gómez-Almaguer D
    Biol Blood Marrow Transplant; 2015 Mar; 21(3):526-30. PubMed ID: 25498924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allogeneic stem cell transplantation as treatment for heavily treated, refractory acute graft-versus-host disease after HLA-mismatched stem cell transplantation.
    Ikegame K; Yoshihara S; Taniguchi Y; Kaida K; Inoue T; Okada M; Taniguchi K; Hasei H; Tamaki H; Fujioka T; Kato R; Soma T; Ogawa H
    Exp Hematol; 2011 Aug; 39(8):880-90. PubMed ID: 21689724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autologous graft-versus-host disease: harnessing anti-tumor immunity through impaired self-tolerance.
    Kline J; Subbiah S; Lazarus HM; van Besien K
    Bone Marrow Transplant; 2008 Mar; 41(6):505-13. PubMed ID: 18026144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of high-stringency CD8 depletion of donor leukocyte infusions after allogeneic hematopoietic stem cell transplantation.
    Orti G; Lowdell M; Fielding A; Samuel E; Pang K; Kottaridis P; Morris E; Thomson K; Peggs K; Mackinnon S; Chakraverty R
    Transplantation; 2009 Dec; 88(11):1312-8. PubMed ID: 19996931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
    Talmadge JE
    Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current trends in clinical studies of allogeneic hematopoietic stem cell transplantation.
    Pilon S; Jedrysiak D; Sheppard D; Bredeson CN; Tay J; Allan DS
    Biol Blood Marrow Transplant; 2015 Feb; 21(2):364-70. PubMed ID: 25445635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.